Articles from The Lundquist Institute for Biomedical Innovation

A one-year prospective study found that very high cholesterol in 100 otherwise metabolically healthy individuals on a ketogenic diet for an average of 5 years did not correlate with atherosclerosis.

Los Angeles, CA, March 24, 2025 (GLOBE NEWSWIRE) -- Mucormycosis, a fungal infection caused by Mucorales, has high mortality rates in people with weakened immune systems and those suffering from severe trauma like burns, blast injuries or victims of natural disasters. The disease caused serious infection among COVID-19 patients treated with high doses of corticosteroids with mortality rates close to 60 percent. In the United States, there are approximately 4,000 cases per year with a rate of 200,000 in Southeast Asia where the disease is endemic to India. While vaccines and immunotherapies are available for viruses and bacteria, effective antifungal immunotherapies for mucormycosis, specifically, are lacking. 

Los Angeles, California, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is pleased to announce the appointment of Joe W. Ramos, PhD, as its new President and Chief Executive Officer, effective January 21, 2025. Dr. Ramos, a renowned cancer researcher and experienced scientific leader, brings decades of expertise in advancing biomedical innovation and fostering collaborative research initiatives.

Los Angeles, California, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is proud to announce the receipt of a $2 million grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute (NIH NHLBI). The award – Award Number R44HL167289 – will fund the development of a highly sensitive and specific point-of-care test (POCT) aimed at detecting allergic Immunoglobulin E (IgE) associated with asthma triggers.

Los Angeles, California, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, in collaboration with Mayo Clinic, is proud to announce that Dr. Denise Al Alam and her co-Principal Investigator colleague, Dr. Christina Pabelick from the Mayo Clinic, Rochester, MN have been awarded a prestigious R01 Grant from the National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI). The grant, totaling $2,457,071, has been allocated for their groundbreaking project entitled “Cellular Senescence in Trisomy 21 Lung Disease,” which commenced on September 1, 2024.

TLI Welcomes a New Incoming Board Member and Thanks Two Outgoing Members

The study found that the blood-brain barrier crossing anti-inflammatory anakinra was safe and associated with improved neurobehavioral and functional outcomes in Sanfilippo syndrome

The award recognizes TLI’s WIC Program for Outstanding Achievement in Supporting and Promoting Breastfeeding Among It Participants

Becoming highly pediatric-ready could decrease child mortality rates by up to 76%

Groundbreaking Research Published in Antimicrobial Agents and Chemotherapy

The proposed sensor has the potential to not only revolutionize COPD management but also to impact healthcare by incorporating wearable electronics into chronic disease management

Dr. Yoshihara will investigate cutting-edge transcriptional gene regulation processes

The project will take a pioneering approach to unraveling sensory and autonomic neurons in the overproduction of IgE in allergic asthma

American Society of Andrology and the European Academy of Andrology Made the Appointment

The award recognizes the Protect Trial, a clinical trial jointly led by Dr. Miller and senior investigator Susan Huang, MD, MPH, Chancellor’s Professor at the University of California, Irvine

AHRQ-funded Study Finds “Universal Decolonization” Lowers Hospital Transfers Due to Infection from Methicillin-Resistant Staphylococcus aureus (MRSA)

AHRQ-funded Study Finds “Universal Decolonization” Lowers Hospital Transfers Due to Infection from Methicillin-Resistant Staphylococcus aureus (MRSA)

Research funding will support the development of the new muscle-CPET or “mCPET,” which will provide a new horizon for the diagnostic and prognostic potential of exercise testing.

The research will apply state-of-the-art science to address antibiotic resistant bloodstream infections caused by Staphylococcus aureus (MRSA) and Candida albicans

The gift will facilitate an FDA-approved multi-site clinical trial under the co-direction of Lundquist Investigators, Dr. Charles S. Grob and Dr. Anthony P. Bossis

The NIH Award will Support Dr. Rehan’s and Advent’s Research to Develop and Position Its Novel Aerosolized Vitamin A Formulation for Commercialization to Prevent BPD

Drs. Jerome Rotter & Matt Budoff Study Shows that in Middle-aged to Older Adults the Coronary Artery Calcium Score Improved CHD Risk Discrimination

Gift Will Directly Fund the Benefits Explorer Tool (BET) to Improve Access to Anti-Poverty Resources for Low-Income Families

Award is for the VX-01 monoclonal antibody (mAb) program targeting the debilitating indication of mucormycosis

CDC says Candida auris is spreading at an alarming rate throughout health care facilities in the U.S. and is resistant to several antifungal drugs

Dr. Filler will be feted for his research on fungal infections and vaccines while Dr. Harrington will be celebrated for his work in internal medicine and treating venous thromboembolism (VTE)

The Gift Will be Used to Study the Effects of the Anti-Inflammatory Colchicine in People with Coronary Artery Disease

Findings Published in The Lancet Ebiomedicine Demonstratethe Positive Effect of State-of-the-Art Ingestible Sensor for HIV Therapeutics

The Diagnostic and Wellness Center will be Renamed the Farima Czyzyk Center for Cardiac Research and Wellness